Given the importance of understanding the relationship between sclerostin and CVD risk for evaluating the safety of emerging osteoporosis therapy, our results highlight the need to explore these relationships in more detail, such as the use of Mendelian randomization, where further studies are required given the conflicting findings from investigations performed to date.(52, 53). The gene discussed is SOST; the disease is osteoporosis.